Colon Cancer


Many Early Onset Colon Cancers are Caused by Genetic Mutations Passed Through Families (04-25-2018)

CancerConnect News: One in every six colorectal cancer patients (16 percent) diagnosed under age 50 has at least one inherited genetic mutation that increases his or her cancer risk and many of these mutations could go undetected with the current screening... Continue Reading

Managing Side Effects From EGFR Inhibitors (04-10-2018)

CancerConnect News: Epidermal Growth Factor Receptor (EGFR) inhibitor drugs are a type of precision cancer medicine commonly used to treat lung, colon, head and neck and other cancers that over express the EGFR.  There are several EGFR inhibitor drugs... Continue Reading

Diagnosed with Colon Cancer: 10 Tips on How to Get The Most From Your Doctor (02-21-2018)

1) Choose Your Doctor Carefully Medical oncologists are the primary doctors involved with colon cancer and work in collaboration with surgeons and gastroenterologists. Pick a medical oncologist carefully, rely on people you trust including nurses and... Continue Reading

Ulixertinib A First-in-class ERK Inhibitor Shows Early Efficacy in Patients With Advanced Cancers (01-8-2018)

CancerConnect News: The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose cancers had mutations in the MAPK cell-signaling pathway, according to data from a recent phase 1 clinical... Continue Reading

Start 2018 Right: Plan for Cancer Screening and Save Lives! (01-5-2018)

Screening guidelines should initiate conversations with your healthcare team.  Charles H Weaver MD, Editor CancerConnect CancerConnect News: The goal of cancer screening is to find disease at early stages in people who are otherwise asymptomatic—before... Continue Reading

Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer (10-16-2017)

Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers.  Ensuring patients undergo genomic sequencing to determine if they have treatable targets is increasingly important to ensure patients... Continue Reading

NSAIDs Decrease Risk of Colorectal Cancer (09-18-2017)

Nonsteroidal anti-inflammatory drugs (NSAIDS) are medicines that are used for the treatment of a wide range of musculoskeletal illnesses including spinal disorders, osteoarthritis and inflammatory conditions like rheumatoid arthritis. NSAIDs effectively... Continue Reading

Fitness in Middle Age Reduces Cancer Risk in Men (06-21-2013)

In a large, long-term study, men with good cardiovascular fitness in middle age were less likely to develop and die from colorectal and lung cancers. These results were presented at 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). Regular... Continue Reading

Erbitux Plus FOLFIRI Outperforms Avastin Plus FOLFIRI for First-Line Treatment of Metastatic Colorectal Cancer (06-20-2013)

For the initial (first-line) treatment of metastatic colorectal cancer with no KRAS gene mutations, the combination of Erbitux® (cetuximab) and FOLFIRI chemotherapy was more effective than the combination of Avastin® (bevacizumab) and FOLFIRI. These... Continue Reading

Delay in Chemotherapy Increases Risk of Death in Colorectal Cancer (04-29-2011)

When chemotherapy for colorectal cancer is delayed by more than four weeks following surgery, patients face an increased risk of death. These findings were recently reported at the American Society of Clinical Oncology’s annual Gastrointestinal Cancers... Continue Reading

Next Page »